A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft

Leukemia & Lymphoma
Kirsty J ThomsonDavid C Linch

Abstract

Treatment options for patients who relapse following autologous transplantation for Hodgkin's lymphoma are limited. There are anecdotal reports of lengthy remissions following second autologous procedures, although treatment-related toxicity can be significant. We report a single centre experience of second autologous transplant performed in seven highly selected patients, who relapsed following initial high-dose therapy. They were all young and had slow tempo disease, which was still sensitive to conventional dose chemotherapy. All received BEAM conditioning for the first transplant, and six of the seven received BEAM for the second. All six of these patients regenerated successfully and with no delay, the final patient dying during the procedure following alternative conditioning. Only one case of presumed carmustine-related pneumonitis was seen, which responded rapidly to corticosteroid therapy. Four patients have subsequently relapsed, of whom three have died at 29, 33, and 38 months postprocedure. One is alive with active disease at 68 months, and the final two are alive and in continuing complete remission at 104 and 68 months.

References

Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J E AndersonJ E Sanders
Nov 1, 1993·Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine·T H BurwinkelS A Carson
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L GajewskiM M Horowitz
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N MilpiedAnthony H Goldstone
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E VandenbergheAnthony H Goldstone
Jul 13, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SantoroV Diehl
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L J Johnston, Sandra J Horning
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra J HorningSaul A Rosenberg
Jun 1, 2002·Bone Marrow Transplantation·T S LinE A Copelan

Citations

May 10, 2007·Leukemia & Lymphoma·David S Ritchie
Aug 20, 2008·British Journal of Haematology·Karl S PeggsAnna Sureda
May 16, 2008·Expert Opinion on Therapeutic Targets·Christian KoeneckeAnke Franzke
May 14, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gordon CookBritish Society of Blood & Marrow Transplantation Clinical Trials Committee
Mar 22, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Amber M BradleyDavid DeRemer
Oct 15, 2013·British Journal of Haematology·Graham P CollinsKarl S Peggs
Feb 3, 2016·Radiology and Oncology·Barbara Jezeršek Novaković
Nov 13, 2015·European Journal of Haematology·Barbara Jezeršek Novaković
Jul 27, 2020·Nature Reviews. Disease Primers·Joseph M ConnorsNancy L Bartlett

Related Concepts

Beam Protocol
Antineoplastic Chemotherapy Protocols
BiCNU
Cytonal
Graft Survival
Hodgkin Lymphoma, Lymphocyte Depletion
Medphalan
Condyline
Relapse
Remission Induction

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2021 Meta ULC. All rights reserved